This is a preprint.
Genomic Medicine Guidance: A Point-of-Care App for Heritable Thoracic Aortic Diseases
- PMID: 38234729
- PMCID: PMC10793513
- DOI: 10.1101/2023.12.22.23299696
Genomic Medicine Guidance: A Point-of-Care App for Heritable Thoracic Aortic Diseases
Update in
-
Development and Assessment of a Point-of-Care Application (Genomic Medicine Guidance) for Heritable Thoracic Aortic Disease.JMIRx Med. 2024 Oct 8;5:e55903. doi: 10.2196/55903. JMIRx Med. 2024. PMID: 39378357 Free PMC article.
Abstract
Genetic testing can determine familial and personal risks for heritable thoracic aortic aneurysms and dissections (TAD). The 2022 ACC/AHA guidelines for TAD recommend management decisions based on the specific gene mutation. However, many clinicians lack sufficient comfort or insight to integrate genetic information into clinical practice. We therefore developed the Genomic Medicine Guidance (GMG) app, an interactive point-of care tool to inform clinicians and patients about TAD diagnosis, treatment, and surveillance. GMG is a REDCap-based app that combines publicly available genetic data and clinical recommendations based on the TAD guidelines into one translational education tool. TAD genetic information in GMG was sourced from the Montalcino Aortic Consortium, a worldwide collaboration of TAD centers of excellence, and the NIH genetic repositories ClinVar and ClinGen. The app streamlines data on the 13 most frequently mutated TAD genes with 2,286 unique pathogenic mutations that cause TAD so that users receive comprehensive recommendations for diagnostic testing, imaging, surveillance, medical therapy, preventative surgical repair, as well as guidance for exercise safety and management during pregnancy. The app output can be displayed in a clinician view or exported as an informative pamphlet in a patient-friendly format. The overall goal of the GMG app is to make genomic medicine more accessible to clinicians and patients, while serving as a unifying platform for research. We anticipate that these features will be catalysts for collaborative projects that aim to understand the spectrum of genetic variants that contribute to TAD.
Keywords: aortic dissection; decision support; genomic medicine; point-of-care; thoracic aortic aneurysm.
Conflict of interest statement
Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Musunuru K., Hershberger R. E., Day S. M., Klinedinst N. J., Landstrom A. P., Parikh V. N., Prakash S., Semsarian C., & Sturm A. C. (2020). Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. Circulation. Genomic and Precision Medicine, 13(4), e000067–e000067 - PubMed
-
- Robin N., Tabereaux P., Benza R., Korf B. (2007). Genetic Testing in Cardiovascular Disease. J Am Coll Cardiol, Aug, 50 (8) 727–737. - PubMed
-
- Isselbacher E. M., Preventza O., Black J. H. III, Augoustides J. G., Beck A. W., Bolen M. A., Braverman A. C., Bray B. E., Brown-Zimmerman M. M., Chen E. P., Collins T. J., DeAnda J., Fanola C. L., Girardi L. N., Hicks C. W., Hui D. S., Schuyler Jones W., Kalahasti V., Kim K. M., … Woo Y. J. (2022). 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation (New York, N.Y.), 146(24), e334–e482. 10.1161/CIR.0000000000001106 - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources